Deal Library / Pharma BD Deal Intelligence

Other Deals

The Pharma Closeout tracks 82 deals, $322.5B in disclosed deal value, 65 with a post-close Outcome Score for Other.

Median Critic Score: 75  ·  Median Outcome Score: 50

Best outcome: Watson Pharmaceuticals (Actavis Inc.) / Actavis plc (97)  ·  Weakest outcome: Celera Genomics Group / Paracel Inc. (10)

All 82 deals

• Watson Pharmaceuticals (Actavis Inc.) / Actavis plc — 2012 · $5.9B · Worked — the deal delivered on its rationale.
• Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. — 2016 · $17.6B · Worked — the deal delivered on its rationale.
• Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) — 2013 · $1.3B · Worked — the deal delivered on its rationale.
• Stryker Corporation / MAKO Surgical Corp. — 2013 · $1.6B · Worked — the deal delivered on its rationale.
• Pamplona Capital Management, LLP / PAREXEL International Corporation — 2017 · $5.0B · Worked — the deal delivered on its rationale.
• DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products — 2013 · $2.6B · Worked — the deal delivered on its rationale.
• Thermo Fisher Scientific Inc. / Patheon N.V. — 2017 · $7.2B · Worked — the deal delivered on its rationale.
• Sanofi S.A. / Boehringer Ingelheim GmbH (consumer healthcare business swap) — 2016 · $25.1B · Worked — the deal delivered on its rationale.
• Bain Capital Private Equity / Cinven Partners (Nidda Healthcare Holding AG) / STADA Arzneimittel — 2017 · $6.1B · Worked — the deal delivered on its rationale.
• Boston Scientific Corporation / Endo International plc (American Medical Systems Men's Health and Prostate Health) — 2015 · $1.6B · Worked — the deal delivered on its rationale.
• Zoetis Inc. / PHARMAQ Holding AS — 2015 · $765M · Worked — the deal delivered on its rationale.
• American Home Products Corporation / BASF AG (Cyanamid agricultural divestiture) — 2000 · $3.8B · Worked — the deal delivered on its rationale.
• Danaher Corporation / Pall Corporation — 2015 · $13.6B · Worked — the deal delivered on its rationale.
• Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) — 2011 · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) — 2018 · $12.7B · Worked — the deal delivered on its rationale.
• Thermo Fisher Scientific Inc. / Dionex Corporation — 2010 · $2.1B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Genia Technologies, Inc. — 2014 · $350M · Largely worked — most objectives met.
• Pfizer Inc. / Capsugel (Pfizer divestiture to KKR) — 2011 · $2.4B · Largely worked — most objectives met.
• AstraZeneca PLC / Aspen Global Inc. (Aspen Pharmacare) — 2016 · $770M · Largely worked — most objectives met.
• Laboratory Corporation of America Holdings / Genzyme Genetics (business unit) — 2010 · $925M · Largely worked — most objectives met.
• Reckitt Benckiser plc / Schiff Nutrition International, Inc. — 2012 · $1.4B · Largely worked — most objectives met.
• Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited — 2014 · $4.0B · Largely worked — most objectives met.
• Genzyme Corporation / Biomatrix Inc. — 2000 · $700M · Largely worked — most objectives met.
• Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited — 2010 · $15M · Largely worked — most objectives met.
• Pfizer Inc. / Alacer Corp. — 2011 · Largely worked — most objectives met.
• Roche Holding AG / Verum Diagnostica GmbH — 2011 · $17M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / BioImagene, Inc. — 2010 · $100M · Mixed — partial payoff, real shortfalls.
• Abbott Laboratories / Piramal Healthcare (Healthcare Solutions Business) — 2010 · $3.7B · Mixed — partial payoff, real shortfalls.
• Stryker Corporation / Gaymar Industries — 2010 · $150M · Mixed — partial payoff, real shortfalls.
• ICU Medical, Inc. / Pfizer Inc. (Hospira Infusion Systems business) — 2016 · $1.0B · Mixed — partial payoff, real shortfalls.
• Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited — 2015 · $4.0B · Mixed — partial payoff, real shortfalls.
• Mallinckrodt plc / Cadence Pharmaceuticals, Inc. — 2014 · $1.4B · Mixed — partial payoff, real shortfalls.
• Aetna Inc. / Coventry Health Care, Inc. — 2012 · $7.3B · Mixed — partial payoff, real shortfalls.
• Nestle SA / Pfizer Nutrition (Pfizer Inc. infant nutrition unit) — 2012 · $11.8B · Mixed — partial payoff, real shortfalls.
• Grifols, S.A. / Novartis Diagnostics (blood transfusion unit) — 2013 · $1.7B · Mixed — partial payoff, real shortfalls.
• Mylan Inc. / Agila Specialties (Strides Arcolab) — 2013 · $1.8B · Mixed — partial payoff, real shortfalls.
• Lonza Group AG / Capsugel S.A. — 2016 · $5.5B · Underwhelmed — fell short of the thesis.
• Watson Pharmaceuticals (Actavis Inc.) / Specifar Pharmaceuticals S.A. — 2011 · $562M · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / GlaxoSmithKline Pharmaceuticals Limited (India) — minority stake increase — 2013 · $1.0B · Underwhelmed — fell short of the thesis.
• Lonza Group AG / Capsugel S.A. (KKR portfolio) — 2016 · $5.5B · Underwhelmed — fell short of the thesis.
• Stryker Corporation / Trauson Holdings Company Limited — 2013 · $764M · Underwhelmed — fell short of the thesis.
• Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) — 2012 · $60M · Underwhelmed — fell short of the thesis.
• Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) — 2014 · $5.3B · Underwhelmed — fell short of the thesis.
• Allergan plc / Zeltiq Aesthetics, Inc. — 2017 · $2.5B · Underwhelmed — fell short of the thesis.
• Perrigo Company plc / Elan Corporation plc — 2013 · $8.6B · Underwhelmed — fell short of the thesis.
• Akorn, Inc. / Hi-Tech Pharmacal Co. Inc. — 2013 · $640M · Did not work — the deal failed to deliver.
• Endo Health Solutions Inc. / Paladin Labs Inc. — 2013 · $1.6B · Did not work — the deal failed to deliver.
• Roche Holding AG / Santaris Pharma A/S — 2014 · $450M · Did not work — the deal failed to deliver.
• Endo International plc / DAVA Pharmaceuticals, Inc. — 2014 · $600M · Did not work — the deal failed to deliver.
• Hospira Inc. / Javelin Pharmaceuticals, Inc. — 2010 · $145M · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Actavis Generics business) — 2016 · $40.5B · Did not work — the deal failed to deliver.
• Allergan plc / Kythera Biopharmaceuticals, Inc. — 2015 · $2.1B · Did not work — the deal failed to deliver.
• Endo Health Solutions Inc. / Boca Pharmacal, LLC — 2014 · $225M · Did not work — the deal failed to deliver.
• Pernix Therapeutics Holdings, Inc. / Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. — 2012 · $102M · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Anda Inc.) — 2016 · $500M · Did not work — the deal failed to deliver.
• Endo Health Solutions Inc. / Boca Pharmacal, LLC — 2013 · $225M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Icagen, Inc. — 2011 · $56M · Did not work — the deal failed to deliver.
• Endo International plc / Grupo Farmaceutico Somar SAPI de CV — 2014 · $270M · Did not work — the deal failed to deliver.
• Endo Pharmaceuticals Inc. / Qualitest Pharmaceuticals — 2010 · $1.2B · Did not work — the deal failed to deliver.
• Endo Pharmaceuticals Inc. / SkyePharma plc — 2003 · $120M · Did not work — the deal failed to deliver.
• Endo International plc / Par Pharmaceutical Holdings, Inc. — 2015 · $8.1B · Did not work — the deal failed to deliver.
• Endo Pharmaceuticals Inc. / American Medical Systems Holdings, Inc. — 2011 · $2.9B · Did not work — the deal failed to deliver.
• Endo Pharmaceuticals Inc. / Penwest Pharmaceuticals Co. — 2010 · $144M · Did not work — the deal failed to deliver.
• Mallinckrodt plc / InfaCare Pharmaceutical Corporation — 2017 · $425M · Did not work — the deal failed to deliver.
• Celera Genomics Group / Paracel Inc. — 2000 · $245M · Did not work — the deal failed to deliver.
• Apotex Inc. / Cumberland Pharmaceuticals branded U.S. commercial business — 2026 · $100M
• AbbVie Inc. / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $745M
• Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC — 2026 · $1.1B
• Eurobio Scientific / CareDx Lab Products business — 2026 · $170M
• Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. — 2025 · $256M
• Catalent, Inc. / Bettera Holdings, LLC — 2021 · $1.0B
• Eli Lilly and Company / Asahi Kasei Pharma — 2021 · $230M
• EQT Private Capital / Recipharm AB — 2021 · $2.8B
• Hypera S.A. / Takeda Pharmaceutical Company Ltd. — 2020 · $825M
• 3M Company / M*Modal — 2019 · $1.0B
• Boston Scientific Corporation / Vertiflex, Inc. — 2019 · $465M
• Eli Lilly and Company / Centrexion Therapeutics Corporation — 2019 · $575M
• Fresenius Kabi AG / Akorn, Inc. — 2017 · $4.8B
• Teva Pharmaceutical Industries Ltd. / Mylan N.V. — 2015 · $40.0B
• Mylan N.V. / Perrigo Company plc — 2015 · $26.0B
• Bayer AG / Schiff Nutrition International, Inc. — 2012 · $1.2B
• Valeant Pharmaceuticals International, Inc. / Sanitas — 2011 · $440M

← Deal Library  ·  Interactive search  ·  How we score deals